The words you are searching are inside this book. To get more targeted content, please make full-text search by clicking here.
Home Explore BioSpectrum Asia April 2024
View in Fullscreen

Addressing Accessibility and Affordability of CELL & GENE THERAPIES
Cell and gene therapies (CGT) are one of the hottest sectors in the pharmaceutical industry. Quite a few companies in the field are making remarkable advancements toward potentially curative treatments for challenging diseases using groundbreaking science. With lower R&D development costs than in advanced markets, China is becoming an attractive market for the development of CGT, and therefore may emerge as a strong competitor of overseas-made CGT, notes a
GlobalData report. Bayer AG, recently announced the global expansion of its life science incubator network, Bayer Co. Lab, to Shanghai, China and Kobe, Japan. The new site in China will focus on oncology and CGT innovations. While India lags behind China in the production of cell and gene therapies, a wave of new biotech startups is emerging to address this challenge. Immuneel Therapeutics and ImmunoACT are currently developing CAR-T cell therapies. The latter’s NexCAR19 therapy received approval from India's Central Drug Standards Control organisation (CDSCO) for treating relapsed or refractory B-cell lymphomas and leukaemia. Despite a steady stream of regulatory approvals and promising growth prospects, the high manufacturing costs associated with these therapies often render them inaccessible to the majority of patients. To address this issue, companies are actively striving to streamline and optimise the highly intricate and labour-intensive process of cell and gene therapy manufacturing.

Like this book? You can publish your book online for free in a few minutes!
Share

Related Publications

Discover the best professional documents and content resources in AnyFlip Document Base.
Search
Published by MMA Media, 2024-03-29 05:26:08

BioSpectrum Asia April 2024

Addressing Accessibility and Affordability of CELL & GENE THERAPIES
Cell and gene therapies (CGT) are one of the hottest sectors in the pharmaceutical industry. Quite a few companies in the field are making remarkable advancements toward potentially curative treatments for challenging diseases using groundbreaking science. With lower R&D development costs than in advanced markets, China is becoming an attractive market for the development of CGT, and therefore may emerge as a strong competitor of overseas-made CGT, notes a
GlobalData report. Bayer AG, recently announced the global expansion of its life science incubator network, Bayer Co. Lab, to Shanghai, China and Kobe, Japan. The new site in China will focus on oncology and CGT innovations. While India lags behind China in the production of cell and gene therapies, a wave of new biotech startups is emerging to address this challenge. Immuneel Therapeutics and ImmunoACT are currently developing CAR-T cell therapies. The latter’s NexCAR19 therapy received approval from India's Central Drug Standards Control organisation (CDSCO) for treating relapsed or refractory B-cell lymphomas and leukaemia. Despite a steady stream of regulatory approvals and promising growth prospects, the high manufacturing costs associated with these therapies often render them inaccessible to the majority of patients. To address this issue, companies are actively striving to streamline and optimise the highly intricate and labour-intensive process of cell and gene therapy manufacturing.

Keywords: gene therapy,Cell therapy

Asia Bio Partnering will gather biotech and pharma leaders from around the world with hundreds of emerging innovators across Asia Pacific to advance dealmaking in Asia. April 24–25, 2024 | Singapore April 29–30, 2024 | Virtual Network with 500+ attendees at the gateway to Asia’s emerging innovation. with over 2,500 one-to-one meetings. Engage with sponsors and exhibitors at Asia Bio Partnering Forum’s active exhibit. Learn more informaconnect.com/asia-bio-partnering-forum Your Gateway to Asia’s Emerging Inovation


Trailblazing Innovation & Collaborations in ADC Drug Development in Asia June 25-27, 2024 | Incheon, South Korea www.worldadc-asia.com Meet 150+ ADC Experts Including: Ziping Wei Chief Executive Officer Bliss Biopharma Tse Wen Chang Founder & Chairman Immunwork Jun Ge Executive Director, Head of China Clinical Development Gilead Heidi Wang Chief Executive Officer OBI Pharma Yasuyuki Kaneta Senior Director Daiichi Sankyo Sun-Hwa Lee Vice Chief Scientific Officer Novelty Nobility ASIA 2024 3rdANNUAL SCAN TO LEARN MORE +1 617 455 4188 @ [email protected] www.worldadc-asia.com Antibody Drug Conjugates World ADC Event Series @World_ADC #WorldADC


Click to View FlipBook Version